These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Management of risk of glucocorticoid-induced osteoporosis due to systemic administration in general practice in Denmark. Nielsen BR; Jørgensen NR; Schwarz P Eur J Gen Pract; 2007; 13(3):168-71. PubMed ID: 17853181 [No Abstract] [Full Text] [Related]
5. The safe and appropriate use of systemic glucocorticoids in treating dermatologic disease. Werth VP J Am Acad Dermatol; 2013 Jan; 68(1):177-8. PubMed ID: 23244375 [No Abstract] [Full Text] [Related]
6. Osteoporosis in health and disease: a dermatologist's perspective. Lamb A; Werth V Dermatol Clin; 2006 Apr; 24(2):241-9, vii. PubMed ID: 16677970 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of osteoporosis and the use of bone protective therapies in dermatology clinic patients on long-term glucocorticoids. Abell S; Zeimer H; Chong A; MacIsaac RJ Australas J Dermatol; 2015 May; 56(2):147-8. PubMed ID: 25900638 [No Abstract] [Full Text] [Related]
10. Prevention of glucocorticoid-induced osteoporosis: why are we doing so poorly? Yood RA J Rheumatol; 2006 Aug; 33(8):1461-3. PubMed ID: 16881101 [No Abstract] [Full Text] [Related]
11. [Osteoporosis: What have the Osteology Society's guidelines done?. Interview by Wiebke Kathmann]. Scheidt-Nave C Dtsch Med Wochenschr; 2005 Oct; Suppl 1():88. PubMed ID: 16379255 [No Abstract] [Full Text] [Related]
13. Missed opportunities in physician management of glucocorticoid-induced osteoporosis? Ramsey-Goldman R Arthritis Rheum; 2002 Dec; 46(12):3115-20. PubMed ID: 12483714 [No Abstract] [Full Text] [Related]
14. [Corticosteroid therapy in dermatology]. Tronnier H Z Allgemeinmed; 1969 Jul; 45(21):985-94. PubMed ID: 5354164 [No Abstract] [Full Text] [Related]
15. How to manage patients on long-term oral corticosteroids: recommendations from available guidelines. Pal B Clin Exp Rheumatol; 1997; 15(4):341-2. PubMed ID: 9272291 [No Abstract] [Full Text] [Related]
16. Systemic glucocorticoids: important issues and practical guidelines for the dermatologist. Dodiuk-Gad RP; Ish-Shalom S; Shear NH Int J Dermatol; 2015 Jun; 54(6):723-9. PubMed ID: 25683616 [TBL] [Abstract][Full Text] [Related]
17. 'Down to skin and bone'. Cameron F Australas J Dermatol; 2000 Aug; 41(3):146-8. PubMed ID: 10954984 [No Abstract] [Full Text] [Related]
18. [Osteoporosis in rheumatic diseases: role of glucocrticoids (part I)]. Nasonov EL; Skripnikova IA Klin Med (Mosk); 1997; 75(10):12-8. PubMed ID: 9490330 [No Abstract] [Full Text] [Related]
19. Glucocorticoid-induced osteoporosis in inflammatory bowel disease. Lidofsky S; Smith J Med Health R I; 2009 Apr; 92(4):128-30. PubMed ID: 19452756 [TBL] [Abstract][Full Text] [Related]
20. [Major side effects of systemic glucocorticoid]. Kudo C Nihon Rinsho; 2015 Feb; 73 Suppl 2():317-21. PubMed ID: 25831775 [No Abstract] [Full Text] [Related] [Next] [New Search]